Commentary|Videos|June 25, 2024

Complexities in Data Management

In part 1 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions discusses the current landscape of data collection in clinical trials and the growing complexity of protocols.

ACT: What are some of the biggest challenges you are currently seeing with data management in clinical trials?

Lacroix: Since I've been in industry for over 20 years, the complexity of protocols which we continually hear; you talk to people in industry—we're going from one indication, one study drug, to multiple indications, multiple study drugs. The majority of the trials that we're seeing at eClinical are platform trials, basket trials, and all of these master protocols and adaptive trials that are extremely complex. In addition to that, we're seeing a lot of different data types and data sources that we've never seen before, and they're just continuing to grow. Coming from historical trials where we had EDC (electronic data capture); it’s a very site-centric data collection. We still see EDC, but we're seeing a lot of other data acquisition tools that are adding complexity to that diversity of data sources and data types. The volume as well; the volume of data is very large. We're processing extremely large data sets and managing all of those data flows and for data managers, it's very different. We're trying to coordinate, manage, and work with multiple stakeholders across study teams, so people often don't think about that part of it in that not only are the protocols getting more complex, but it introduces new players, new stakeholders, more decision-makers at the table that we have to coordinate and manage. Of course, with all of this, there's continual pressure to do it faster. We want data insight sooner—in that reduction in cycle time and cost and risk reduction—that pressure is just continuing to grow in the face of all of this complexity.


Related to this article

What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.